Oncolytics Biotech
Oncolytics is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential across cancer types
Basic Information
- Category: pharmaceutical industry
- Founded: 1998
- Website: http://www.oncolyticsbiotech.com
Documented Facts
- Email: info@oncolyticsbiotech.com (No linked source recorded for this statement.)
- Founded: 1998 (No linked source recorded for this statement.)
- Website: http://www.oncolyticsbiotech.com (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: NV (No linked source recorded for this statement.)
- Stock ticker: ONCY (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Oncolytics Biotech — Official Site (official)
- Oncolytics Biotech — Wikipedia (reference)
- ONCOLYTICS BIOTECH INC — SEC EDGAR (reference)
Citation Guidance
Explore pharmaceutical industry profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Oncolytics Biotech.
- Canonical profile: https://brandsource.ai/brands/oncolytics-biotech
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/oncolytics-biotech/json-ld
- Citation profile API: https://brandsource.ai/api/brands/oncolytics-biotech/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Oncolytics is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential across cancer types
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 6 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.